Real-Life Individual Comparison of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Heart Failure and Diabetes Mellitus

Basit Öğe Kaydı
dc.authoridSahin, Anil/0000-0003-3416-5965
dc.contributor.authorYilmaz, Mehmet Birhan
dc.contributor.authorCelik, Ahmet
dc.contributor.authorColluoglu, Tugce
dc.contributor.authorSahin, Anil
dc.contributor.authorUral, Dilek
dc.contributor.authorKanik, Arzu
dc.contributor.authorAta, Naim
dc.date.accessioned2025-05-04T16:47:22Z
dc.date.available2025-05-04T16:47:22Z
dc.date.issued2025
dc.departmentSivas Cumhuriyet Üniversitesi
dc.description.abstractBackgroundSodium-glucose cotransporter-2 inhibitors (SGLT2is) are breakthrough agents for the treatment of type 2 diabetes mellitus (T2DM) and heart failure (HF). However, among patients with HF and T2DM, some uncertainty remains about individual comparisons, including dosing.ObjectivesWe aimed to make a real-life individual comparison of SGLT2is among patients with HF and T2DM.MethodsThis was a subgroup analysis of the Turkish Ministry of Health's National Electronic Database for adult patients with HF (TRends-HF). All-cause mortality (ACM) data up to 7 years were evaluated. Patients with HF and T2DM who were prescribed an SGLT2i were identified, and individual doses of empagliflozin 25 mg, empagliflozin 10 mg, and dapagliflozin 10 mg were compared. For individual comparisons, propensity score-matching analysis was generated as 1:1:1, and disease-modifying therapies (DMTs) for HF were considered.ResultsIn the triple-matched cohort, 1-, 5-, and 7-year survival rates were 95%, 81%, and 76% versus 94%, 78%, and 72% versus 94%, 80%, and 75% for empagliflozin 25 mg, empagliflozin 10 mg, and dapagliflozin 10 mg, respectively. Among patients who were on triple DMT for HF, 1-, 5-, and 7-year survival rates were 95%, 78%, and 70% for empagliflozin 25 mg, 95%, 74%, and 66% for empagliflozin 10 mg, and 94%, 77%, and 69% for dapagliflozin, respectively. Annual emergency department visits were slightly lower with empagliflozin 10 mg and dapagliflozin 10 mg than with empagliflozin 25 mg. A greater proportion of patients on dapagliflozin 10 mg did not experience hospitalization during the 7-year follow-up compared with both doses of empagliflozin, albeit with a small effect size.ConclusionAmong patients with HF and T2DM, SGLT2is are instrumental, and empagliflozin 10 mg remains significantly inferior to dapagliflozin 10 mg and empagliflozin 25 mg in terms of 5- and 7-year ACM.
dc.identifier.doi10.1007/s40256-024-00698-6
dc.identifier.endpage286
dc.identifier.issn1175-3277
dc.identifier.issn1179-187X
dc.identifier.issue2
dc.identifier.pmid39609352
dc.identifier.scopus2-s2.0-85210575992
dc.identifier.scopusqualityQ1
dc.identifier.startpage277
dc.identifier.urihttps://doi.org/10.1007/s40256-024-00698-6
dc.identifier.urihttps://hdl.handle.net/20.500.12418/35568
dc.identifier.volume25
dc.identifier.wosWOS:001366104600001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherAdis Int Ltd
dc.relation.ispartofAmerican Journal of Cardiovascular Drugs
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250504
dc.subjectCardiovascular Outcomes
dc.subjectEmpagliflozin
dc.titleReal-Life Individual Comparison of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Heart Failure and Diabetes Mellitus
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksyonu
Scopus İndeksli Yayınlar Koleksiyonu